Aflibercept (2.0 mg)

DRUG11 trials

Sponsors

Northern California Retina Vitreous Associates, EyePoint Pharmaceuticals, Inc., Exegenesis Bio, Sierra Eye Associates, CMH Multan Institute of Medical Sciences

Conditions

DMEDiabetic Macular EdemaDiabetic Macular Edema (DME)Diabetic Retinopathy, DRMacular Edema With Central Retinal Vein OcclusionsNeovascular (Wet) Age-related Macular Degeneration (AMD)Neovascular Age-Related Macular Degeneration (nAMD)Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD

Phase 1

A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

Active, not recruitingNCT06817343

Exegenesis BioNeovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)

Start: 2024-09-10End: 2029-02-01Target: 12Updated: 2026-04-08

Phase 2

Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)

RecruitingNCT06942520

Sierra Eye AssociatesDiabetic Macular Edema

Start: 2025-03-18End: 2027-12-31Target: 18Updated: 2025-04-24

Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration

RecruitingNCT07776522

West China HospitalNeovascular Age-Related Macular Degeneration (nAMD) Wet AMD

Start: 2026-08-31End: 2032-01-14Target: 50Updated: 2026-08-20

Phase 3

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

Active, not recruitingNCT06668064

EyePoint Pharmaceuticals, Inc.Wet Age Related Macular Degeneration, wAMD

Start: 2024-10-22End: 2027-08-01Target: 400Updated: 2026-09-03

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Active, not recruitingNCT06683742

EyePoint Pharmaceuticals, Inc.Wet Age Related Macular Degeneration, wAMD

Start: 2024-11-27End: 2027-10-01Target: 400Updated: 2026-09-03

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Active, not recruitingNCT07449936

EyePoint Pharmaceuticals, Inc.Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)

Start: 2026-02-16End: 2028-10-01Target: 240Updated: 2026-09-03

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Active, not recruitingNCT07449923

EyePoint Pharmaceuticals, Inc.Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)

Start: 2026-02-09End: 2028-10-01Target: 240Updated: 2026-09-03

A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO

RecruitingNCT07734844

Kodiak Sciences IncDiabetic Macular Edema (DME)

Start: 2026-08-03End: 2029-09-01Target: 910Updated: 2026-08-21

Phase 4

NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

CompletedNCT01870427

Northern California Retina Vitreous AssociatesMacular Edema With Central Retinal Vein Occlusions

Start: 2013-06-30End: 2016-08-31Updated: 2016-12-08

Unknown Phase

Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema

Enrolling by invitationNCT07338097

CMH Multan Institute of Medical SciencesDiabetic Macular Edema (DME)

Start: 2025-09-07End: 2026-02-07Target: 116Updated: 2026-01-13

Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy

CompletedNCT07526857

Federico II UniversityDiabetic Retinopathy, DR

Start: 2025-01-01End: 2026-01-01Updated: 2026-04-13

Related Papers

Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study.

2019-04-1510 citations